Equillium (EQ) Total Non-Current Liabilities (2017 - 2021)
Equillium (EQ) reported Total Non-Current Liabilities of $16.7 million for Q3 2021, up 17.36% year-over-year from $14.2 million in Q3 2020, and up 10.66% quarter-over-quarter from $15.0 million in Q2 2021.
Equillium (EQ) Total Non-Current Liabilities (2017 - 2021) Analysis & Trends
Equillium (EQ) has 5 years of Total Non-Current Liabilities data on file, last reported at $16.7 million in Q3 2021.
- Total Non-Current Liabilities for Q3 2021 came in at $16.7 million, up 17.36% year-over-year; the trailing twelve-month figure through Sep 2021 was $16.7 million (up 17.36% YoY), and the FY2020 annual result was $15.5 million, up 14.42% from the prior year.
- Total Non-Current Liabilities grew to $16.7 million in Q3 2021 per EQ's latest filing, from $15.0 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $16.7 million in Q3 2018 and troughed at $163000.0 in Q2 2019.
- A 5-year average of $11.2 million and a median of $13.7 million in 2019 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2018 and 2020: Total Non-Current Liabilities sank 97.68% in 2018, then soared 7996.32% in 2020.
- A 5-year view of Total Non-Current Liabilities shows it stood at $8.6 million in 2017, then slumped by 97.68% to $200000.0 in 2018, then soared by 6682.0% to $13.6 million in 2019, then gained by 14.42% to $15.5 million in 2020, then climbed by 7.29% to $16.7 million in 2021.
- Business Quant data shows EQ's Total Non-Current Liabilities at $16.7 million in Q3 2021, $15.0 million in Q2 2021, and $14.9 million in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 16.65 Mn |
| Jun 30, 2021 | 15.05 Mn |
| Mar 31, 2021 | 14.92 Mn |
| Dec 31, 2020 | 15.52 Mn |
| Sep 30, 2020 | 14.19 Mn |
| Jun 30, 2020 | 13.20 Mn |
| Mar 31, 2020 | 13.46 Mn |
| Dec 31, 2019 | 13.56 Mn |
| Sep 30, 2019 | 13.89 Mn |
| Jun 30, 2019 | 163,000.00 |
| Mar 31, 2019 | 181,000.00 |
| Dec 31, 2018 | 200,000.00 |
| Sep 30, 2018 | 16.65 Mn |
| Dec 31, 2017 | 8.63 Mn |